UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Exanthematous (morbilliform) drug eruption

Author
Andreas J Bircher, MD
Section Editors
Maja Mockenhaupt, MD, PhD
Jean-Claude Roujeau, MD
Deputy Editor
Rosamaria Corona, MD, DSc

INTRODUCTION

Exanthematous drug eruption, also called morbilliform or maculopapular drug eruption, is the most common type of drug hypersensitivity reaction [1,2]. They are characterized by a diffuse and symmetric eruption of erythematous macules or small papules occurring approximately one week after the initiation of drug treatment. In severe forms, the mucosae (oral, conjunctival, nasal, or anogenital) and skin appendages (hair and nails) may be involved.

This topic will discuss the clinical presentation, diagnosis, and treatment of exanthematous drug eruptions. Drug allergy and other types of cutaneous adverse drug reactions are discussed separately.

(See "Drug allergy: Classification and clinical features".)

(See "Penicillin allergy: Immediate reactions".)

(See "Cephalosporin allergy: Clinical manifestations and diagnosis".)

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Dec 04 00:00:00 GMT 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.
  2. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.
  3. Pichler WJ. Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, Basel 2007. p.168.
  4. Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011; 71:701.
  5. Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4:411.
  6. Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. In: Chemical Immunology, French L (Ed), Karger Publishers, Basel 2012.
  7. Friedmann PS, Pickard C, Ardern-Jones M, Bircher AJ. Drug-induced exanthemata: a source of clinical and intellectual confusion. Eur J Dermatol 2010; 20:255.
  8. Pichler WJ, Adam J, Daubner B, et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010; 94:645.
  9. Litt JZ. Litt's Drug Eruptions and Reactions Manual, 16th ed, Informa Healthcare, London 2010.
  10. Wei CY, Ko TM, Shen CY, Chen YT. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet 2012; 27:132.
  11. Profaizer T, Eckels D. HLA alleles and drug hypersensitivity reactions. Int J Immunogenet 2012; 39:99.
  12. Stokes SC, Tankersley MS. HIV: practical implications for the practicing allergist-immunologist. Ann Allergy Asthma Immunol 2011; 107:1.
  13. Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol 2011; 38:222.
  14. Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009; 8:488.
  15. Whitaker P, Shaw N, Gooi J, et al. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J Cyst Fibros 2011; 10:282.
  16. Spoerl D, Scherer K, Tyndall A. Aspects of allergy in rheumatology. Clin Exp Rheumatol 2011; 29:560.
  17. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000; 55:191.
  18. Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30:352.
  19. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51:297.
  20. Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis 2004; 50:349.
  21. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11:313.
  22. Scherer K, Bircher AJ. Danger Signs in Drug Hypersensitivity. In: Drug Hypersensitivity, Pichler WJ (Ed), W.B. Saunders Co., Philadelphia 2010. p.681.
  23. Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005; 209:201.
  24. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.
  25. Kulthanan K, Chularojanamontri L, Manapajon A, et al. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22:155.
  26. Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009; 70:1258.
  27. Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol 2002; 147:255.
  28. Bircher AJ. Approach to the patient with a drug hypersensitivity reaction - clinical perspectives. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, Basel 2007. p.352.
  29. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58:33.
  30. Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev 2007; :CD005646.
  31. Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65:1357.
  32. Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68:844.